Eli Lilly and Co
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY3541860 in Healthy Japanese and Non-Japanese Participants
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 94
- Registration Number
- NCT05042310
- Locations
- 🇯🇵
P-One Clinic, Hachioji, Tokyo, Japan
A Study of LY3473329 in Healthy Japanese Participants
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT05038787
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1823
- Registration Number
- NCT05026866
- Locations
- 🇺🇸
Marvel Clinical Research, Huntington Beach, California, United States
🇺🇸Accel Research Sites - St. Pete-Largo Clinical Research Unit, Largo, Florida, United States
🇺🇸Coram CVS/Specialty Infusion Services - Mendota Heights, Mendota Heights, Minnesota, United States
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 316
- Registration Number
- NCT05024045
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
- Conditions
- Interventions
- First Posted Date
- 2021-08-27
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 210
- Registration Number
- NCT05024032
- Locations
- 🇨🇳
The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳Zhujiang Hospital, Guangzhou, Guangdong, China
🇨🇳Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China
A Study of [¹⁴C]-LY3484356 in Healthy Female Participants
- Conditions
- Interventions
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT04991766
- Locations
- 🇺🇸
LabCorp CRU, Inc., Madison, Wisconsin, United States
A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 7
- Registration Number
- NCT04992312
- Locations
- 🇺🇸
St. Luke's Regional Medical Center, Boise, Idaho, United States
🇺🇸Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Study of LY3361237 in Participants With Psoriasis
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT04975295
- Locations
- 🇧🇬
MC Comac Medical, Sofia, Bulgaria
🇵🇱All Med - Lodz, Lodz, Poland
🇵🇱Pratia - Warsaw, Warszawa, Poland
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 866
- Registration Number
- NCT04975308
- Locations
- 🇺🇸
USO - Texas Oncology - Allen, Allen, Texas, United States
🇦🇺Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia
🇺🇸Ironwood Cancer & Research Centers, Chandler, Arizona, United States
A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 54
- Registration Number
- NCT04957914
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany